Prognostic factors and prognosis prediction of diffuse large B-cell lymphomaThe prognosis factor of DLBCL was found, and prognosis prediction was possible.As a result of the complete exomam sequence analysis for two groups of extreme cases of R-CHOP or similar treatment, the case of the ...
Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era.Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous ...
Despite recent advances in frontline therapy for diffuse large B-cell lymphoma (DLBCL), at least a third of those diagnosed still will require second or further lines for relapsed or refractory (rel/ref) disease. A small minority of these can be cured wi
Diffuse large B cell lymphoma Stage III: involvement on both sides of the diaphragm Diffuse large B cell lymphoma Stage IV is widespread involvement of 1 or more sites outside the lymphatic systemRisk factors that point to a poorer outcome are older age (>60 years), high level of a substan...
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma in dogs. We evaluated Ki67 immunoexpression and mitotic index (MI) in dogs diagnosed with DLBCL and treated with a 19-wk CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) protocol. Twenty-nine lymph node...
However, the prognostic significance of peripheral lymphocytes and monocytes in lymphoma remains unclear.MethodsWe evaluated the prognostic impact of the absolute lymphocyte count (ALC), absolute monocyte count (AMC), and lymphocyte/monocyte ratio (LMR) in 359 diffuse large B-cell lymphoma (DLBCL) ...
Moreover, in combination with the revised International Prognostic Index (R-IPI), R-IPI-poor/CD109-high was associated with poorer prognosis compared with R-IPI-poor alone. We assessed TGF-β signaling in CD109-depleted Nalm6 cells (a human B-lymphoblastic leukemia/lymphoma cell line), and ...
Early detection of patients with poor risk diffuse large B-cell lymphoma. diffuse large B-cell lymphomaprognosisprognostic markersMore than 60% of patients with diffuse large B-cell lymphoma (DLBCL) will be cured with rituximab,... SEHN,LAURIE,H. - 《Leukemia & Lymphoma》 被引量: 31发表: ...
Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie Ket al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT)...
diffuse large B-cell lymphomaextranodalprognosisrituximabThe addition of rituximab (R) to standard CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy has altered the significance of previously recognized prognostic factors. We sought to re-examine the prognostic utility of (1) ...